ENTRY       D10223                      Drug
NAME        Ibrutinib (JAN/USAN);
            Imbruvica (TN)
PRODUCT     IMBRUVICA (Pharmacyclics LLC)
FORMULA     C25H24N6O2
EXACT_MASS  440.1961
MOL_WEIGHT  440.4971
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG02022  BTK inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
REMARK      Therapeutic category: 4291
            ATC code: L01EL01
            Product: D10223<JP/US>
EFFICACY    Antineoplastic, Bruton's tyrosine kinase inhibitor
  DISEASE   Mantle cell lymphoma [DS:H01464]
            Chronic lymphocytic leukemia [DS:H00005]
            Chronic lymphocytic leukemia (chromosome 17p deletion) [DS:H00005]
            Waldenstr√∂m's macroglobulinemia [DS:H00011]
            Chronic graft versus host disease [DS:H00084]
TARGET      BTK [HSA:695] [KO:K07370]
  PATHWAY   hsa04662(695)  B cell receptor signaling pathway
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EL Bruton's tyrosine kinase (BTK) inhibitors
                 L01EL01 Ibrutinib
                  D10223  Ibrutinib (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Ibrutinib
                D10223  Ibrutinib (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10223  Ibrutinib (JAN/USAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG02022  BTK inhibitor
                D10223  Ibrutinib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               D10223  Ibrutinib
            Drug classes [BR:br08332]
             Antineoplastic
              DG02022  BTK inhibitor
               D10223  Ibrutinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Non-receptor tyrosine kinases
               Tec family
                BTK
                 D10223  Ibrutinib (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10223
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10223
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10223
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10223
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10223
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10223
DBLINKS     CAS: 936563-96-1
            PubChem: 163312254
            ChEBI: 76612
            PDB-CCD: 1E8
ATOM        33
            1   C8x C    12.5300  -16.3800
            2   N5x N    12.5300  -17.7800
            3   C8y C    13.7200  -18.4800
            4   C8y C    14.9800  -17.7800
            5   C8y C    14.9800  -16.3800
            6   N5x N    13.7200  -15.6800
            7   N1a N    13.7200  -19.8800
            8   C8y C    16.3100  -18.2000
            9   N5x N    17.0800  -17.0800
            10  N4y N    16.3100  -15.9600
            11  C1y C    16.8000  -14.6300
            12  O2a O    19.1100  -23.0300
            13  C8y C    18.4100  -21.8400
            14  C8x C    19.1100  -20.6500
            15  C8x C    18.4100  -19.3900
            16  C8y C    17.0100  -19.3900
            17  C8x C    16.3100  -20.5800
            18  C8x C    17.0100  -21.8400
            19  C8y C    20.5100  -23.0300
            20  C8x C    21.2100  -24.2200
            21  C8x C    22.6100  -24.2200
            22  C8x C    23.3100  -23.0300
            23  C8x C    22.6100  -21.7700
            24  C8x C    21.2100  -21.7700
            25  C1x C    18.2000  -14.6300
            26  N1y N    18.9000  -13.3700
            27  C1x C    18.2000  -12.1800
            28  C1x C    16.8000  -12.1800
            29  C1x C    16.1000  -13.3700
            30  C5a C    20.3000  -13.3700
            31  O5a O    20.9300  -12.1100
            32  C2b C    21.0000  -14.5600
            33  C2a C    22.4000  -14.5600
BOND        37
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     3   7 1
            8     4   8 1
            9     8   9 2
            10    9  10 1
            11    5  10 1
            12   11  10 1 #Down
            13   12  13 1
            14   13  14 2
            15   14  15 1
            16   15  16 2
            17   16  17 1
            18   17  18 2
            19   13  18 1
            20   12  19 1
            21   19  20 2
            22   20  21 1
            23   21  22 2
            24   22  23 1
            25   23  24 2
            26   19  24 1
            27   16   8 1
            28   11  25 1
            29   25  26 1
            30   26  27 1
            31   27  28 1
            32   28  29 1
            33   11  29 1
            34   26  30 1
            35   30  31 2
            36   30  32 1
            37   32  33 2
///
